Industry News

• PharmaCyte Biotech proceeding with GMP production of pancreatic cancer product  PharmaCyte announced it has made further important progress in optimizing the complete manufacturing process, including significant improvement of the growth characteristics of the cells from PharmaCyte’s Master Cell Bank after encapsulation.
  May 20, 2019  
• Exact Sciences advances pipeline capabilities with Mayo Clinic  Early research using blood-based methylated DNA markers, identified through the longstanding collaboration between Exact Sciences and Mayo Clinic, demonstrates a potential to achieve 92% sensitivity and 92% specificity for detecting the most common type of pancreatic cancer.
  May 20, 2019  
• Amyris announces receipt of $10 million milestone payment from LAVVAN   Amyris reported it has received from its cannabinoid partner, LAVVAN, a first cash payment of $10 million for having successfully delivered on its first major collaboration milestone. The company expects to bring the first fermentation-derived cannabinoid products to market next year.
  May 20, 2019  
• Catalent completes acquisition of gene therapy leader Paragon Bioservices for $1.2 billion  Catalent announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, a leading viral vector development and manufacturing partner for gene therapies. Paragon has GMP manufacturing projects underway with more than half of the top 40 leading gene therapy developers worldwide.
  May 20, 2019  
• Cocrystal Pharma commences patient enrollment for Hong Kong phase 2a study of CC-31244  Cocrystal Pharma announced today that it has commenced patient enrollment in its Phase 2a study in Hong Kong SAR, China. The Phase 2a open-label study will evaluate safety, tolerability and preliminary efficacy of CC-31244 in combination with Sofosbuvir and Daclatasvir for treatment of hepatitis C.
  May 20, 2019  
• Veracyte unveils new Percepta Genomic Sequencing Classifier for lung cancer diagnosis  Veracyte announced new data demonstrating that its next-generation Percepta® Genomic Sequencing Classifier provides expanded lung cancer risk information that can further guide next steps for patients with lung nodules.
  May 20, 2019  
• BioXcel Therapeutics achieved targeted exposures of BXCL501 for neuropsychiatric diseases  BioXcel Therapeutics announced positive top line data from its Phase 1 pharmacokinetic (bioavailability) and safety study of BXCL501, a proprietary sublingual thin-film formulation of dexmedetomidine (Dex), for acute treatment of agitation across multiple neuropsychiatric indications.
  May 20, 2019  
• Kraig Labs takes possession of factory in Vietnam  Kraig Biocraft announces its subsidiary Prodigy Textiles has taken possession of its factory in Vietnam. The Company is now retrofitting the nearly 50,000 square foot facility to produce its game changing recombinant spider silk materials.
  May 20, 2019  
• Age, gender, disease severity impact adherence to long-term PAP therapy more than thought  ResMed revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy. The study found significant differences in one-year adherence between people of different ages and disease severity levels.
  May 19, 2019  
• Moderna announces publication of preclinical data for chikungunya antibody program  Moderna announced publication of preclinical data in Science Immunology, showing that mRNA encoding a human monoclonal antibody against the chikungunya virus delivered in a proprietary lipid nanoparticle can protect from infection by the virus in vivo.
  May 17, 2019  

   (next 10 articles)